The search for a specific protein that could help diagnose ovarian cancer in its early stages has for years eluded researchers who are seeking a reliable and accurate test for the disease. Instead of searching for a single protein, researchers at the University of Pittsburgh School of Medicine used a new technology to analyze a large number of proteins, or potential biomarkers, from a very small sample of serum from women with ovarian cancer. They identified a combination of several biomarkers that could help detect the disease much earlier than it is currently being diagnosed, according to findings presented at the annual meeting of the American Association for Cancer Research, April 1 to 5 at the Washington Convention Center in Washington, D.C.
"One of the most challenging problems with ovarian cancer is that we lack a reliable and accurate test that can detect it early when it is most responsive to treatment," said Anna E. Lokshin, Ph.D., lead investigator and assistant professor of medicine and pathology at the University of Pittsburgh School of Medicine. "By the time women are diagnosed, their cancers have already spread and are extremely difficult to treat successfully. To improve the long-term outcome for women diagnosed with ovarian cancer, we sought to identify a panel of proteins that could signify the presence of early disease."
In the study, Pitt researchers took advantage of a novel technology called LapMAP that is able to analyze multiple proteins in a single drop of blood or serum. They tested 450 serum samples for 46 biomarkers that had previously been correlated with ovarian cancer and were able to identify a multi-marker panel, comprised of 20 proteins that correctly recognized more than 98 percent of serum samples from women with ovarian cancer, offering higher diagnostic power than any other published assay for ovarian cancer.
"Through further examination, our goal is to develop this screening assay into a diagnostic testPage: 1 2 Related biology news :1
. Triplex assay used to assay duplex genomic DNA2
. Successful development of prototype assays3
. Genesearch Breast Lymph Node assay detects breast cancer metastases with greater sensitivity4
. Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent5
. Molecule by molecule, new assay shows real-time gene activity6
. VCU researchers design new receptor and enhance bioassay to advance drug discovery process7
. Researchers develop assay that could be applied to drug screening8
. Novel canary on a chip sensor measures tiny changes in cell volume; Provides assay results9
. PCRM develops worlds first cruelty-free insulin assay10
. First case of successful ovarian tissue transplantation between two, nonidentical sisters11
. Scientists take next step in understanding potential target for ovarian cancer treatment